Long-term survivor model with bivariate random effects: Applications to bone marrow transplant and carcinoma study data

2008 ◽  
Vol 27 (27) ◽  
pp. 5692-5708 ◽  
Author(s):  
Xin Lai ◽  
Kelvin K. W. Yau
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplant ◽  
Random Effects ◽  
Marrow Transplant ◽  
Study Data ◽  
Term Survivor

Long-Term Immunologic Induction of Donor-Specific Tolerance to Skin Allografts by Bone Marrow Transplant in Rabbits

2003 ◽  
Vol 111 (1) ◽  
pp. 291-297 ◽  
Author(s):  
Yi Biao Wang ◽  
Yutaka Ogawa ◽  
Hideaki Doi ◽  
Kenji Kusumoto ◽  
Tie Nan Jin ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplant ◽  
Marrow Transplant ◽  
Skin Allografts ◽  
Donor Specific Tolerance ◽  
Specific Tolerance

Vinblastine for recurrent Hodgkin's disease following autologous bone marrow transplant.

1998 ◽  
Vol 16 (2) ◽  
pp. 584-588 ◽  
Author(s):  
R Little ◽  
R E Wittes ◽  
D L Longo ◽  
W H Wilson
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplant ◽  
Hodgkin's Disease ◽  
Hodgkin’S Disease ◽  
Performance Status ◽  
Palliative Therapy ◽  
Marrow Transplant ◽  
Additional Treatment ◽  
Low Toxicity

PURPOSE Bone marrow transplant (BMT) can cure recurrent Hodgkin's disease, but more than half of patients will progress and require additional treatment. When this occurs, there are no curative options and palliative therapy is usually indicated. In such patients, we have routinely used long-term vinblastine therapy because of its relatively low toxicity and high activity. PATIENTS AND METHODS We retrospectively reviewed the charts of all patients with Hodgkin's disease who relapsed after autologous BMT since 1991. Of 23 patients, 16 received vinblastine; we also include our index case, who began vinblastine following relapse in 1987. Patients received vinblastine 4 to 6 mg/m2 every 1 to 2 weeks, and continued until evidence of disease progression. RESULTS The 17 patients in this report had a median age of 31 years, performance status of 2, had received a median of three prior regimens, and 12 (71%) patients were advanced stage. Ten (59%) patients had objective responses, of which two (12%) were complete (CR) and eight (47%) were partial (PR). Two additional patients without measurable disease clinically improved for more than 6 months, and 1 patient had stable disease for more than 18 months. With a median follow-up of 20.4 months, the median event-free (EFS) and overall survival were 8.3 and 38.8 months, respectively. The two complete responders remain in remission at 4.6+ and 9+ years. Vinblastine was well tolerated with 3% of cycles associated with fever and neutropenia, and no cumulative or chronic toxicity. CONCLUSION Vinblastine provides effective palliation with low toxicity in recurrent Hodgkin's disease following transplant. These results suggest that long-term vinblastine therapy may be potentially curative and should be considered as initial therapy for such patients.

EXTENDED FOLLOW-UP IN 212 LONG-TERM ALLOGENEIC BONE MARROW TRANSPLANT SURVIVORS ISSUES OF QUALITY OF LIFE

1993 ◽  
Vol 55 (3) ◽  
pp. 551-556 ◽  
Author(s):  
GERHARD M. SCHMIDT ◽  
JOYCE C. NILAND ◽  
STEPHEN J. FORMAN ◽  
FILAR P. FONBUENA ◽  
ANDREW C. DAGIS ◽  
...  
Keyword(s):  
Quality Of Life ◽  
Bone Marrow ◽  
Bone Marrow Transplant ◽  
Marrow Transplant ◽  
Allogeneic Bone Marrow ◽  
Allogeneic Bone ◽  
Allogeneic Bone Marrow Transplant

scholarly journals Hepatitis C virus in long-term bone marrow transplant survivors

2004 ◽  
Vol 33 (12) ◽  
pp. 1181-1185 ◽  
Author(s):  
C A P Ivantes ◽  
H Amarante ◽  
S O Ioshii ◽  
R Pasquini
Keyword(s):  
Bone Marrow ◽  
Hepatitis C Virus ◽  
Hepatitis C ◽  
Bone Marrow Transplant ◽  
Marrow Transplant

Long-Term Immunologic Induction of Donor-Specific Tolerance to Skin Allografts by Bone Marrow Transplant in Rabbits

2003 ◽  
Vol 111 (1) ◽  
pp. 291-297 ◽  
Author(s):  
Yi Biao Wang ◽  
Yutaka Ogawa ◽  
Hideaki Doi ◽  
Kenji Kusumoto ◽  
Tie Nan Jin ◽  
...  
Keyword(s):  
Bone Marrow ◽  
Bone Marrow Transplant ◽  
Marrow Transplant ◽  
Skin Allografts ◽  
Donor Specific Tolerance ◽  
Specific Tolerance
Sign in / Sign up

Export Citation Format

Share Document